Kahira Pharmaceuticals’ profits fall 41.4% in FY2022/23: Egypt

Getty Images

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products

Staff Writer, Arab Finance

October 10, 2023

PHOTO

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 41.42% year-on-year (YoY) decline in net profit after tax for the fiscal year (FY) of 2022/2023, according to the company’s financial statements filed to the Egyptian Exchange (EGX) on October 9th.

CPCI’s net profit after tax stood at EGP 97.091 million for the 12-month period ended June 30th, compared to EGP 165.744 million a FY earlier.

Operating revenue dropped by 9.61% YoY, hitting EGP 1.005 billion from EGP 1.112 billion.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

ZAWYA NEWSLETTERS

RELATED ARTICLES

ZAWYA NEWSLETTERS

LATEST VIDEO